The combination of accelerating revenue growth, improved financial discipline, strong cash position, and rapid clinical progress in the VYD2311 program suggests improved execution and near-term catalyst potential. Traders should monitor for top-line data from the DECLARATION trial in mid-2026 and any trial resizing decision in April 2026.
IVVD drugs
IVVD drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 5 $1.74entry
- T+1 · 9mo ago +3.45%α +4.76% · $1.80
- T+5 · 8mo ago +3.45%α +5.69% · $1.80
- T+20 · 8mo ago −26.44%α −22.65% · $1.28
- T+60 · 6mo ago −29.89%α −41.19% · $1.22
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Invivyd reported strong Q4 and full-year 2025 financial results with PEMGARDA net product revenue of $17.2 million (up 25% YoY) and full-year revenue of $53.4 million (up 110% YoY), while significantly reducing R&D expenses to $38.3 million from $137.3 million. The company ended 2025 with $226.7 million in cash after raising over $200 million, supporting its pivotal DECLARATION Phase 3 trial for VYD2311 with top-line data expected mid-2026.
Key Financial Metrics
Key Facts
- Q4 2025 PEMGARDA net revenue: $17.2M, up 25% YoY and 31% QoQ
- Full-year 2025 PEMGARDA net revenue: $53.4M, up 110% from $25.4M in 2024
- R&D expenses dropped to $38.3M in 2025 from $137.3M in 2024
- Cash and cash equivalents: $226.7M as of Dec 31, 2025, after raising over $200M in 2H 2025
- Net loss narrowed to $52.5M in 2025 from $169.9M in 2024; EPS improved to -$0.30 from -$1.43
- Full enrollment achieved in DECLARATION Phase 3 trial for VYD2311; top-line data expected mid-2026
- FDA granted Fast Track designation for VYD2311 in December 2025
- IDMC recommended expansion of trial to include pregnant and breastfeeding women
Financial Impact
Revenue more than doubled year-over-year to $53.4M with significant cost reductions, leading to a 69% reduction in net loss. Cash position of $226.7M supports clinical development into 2026+.
Risk Factors
- VYD2311 remains investigational; clinical trial outcomes are uncertain
- Revenue is currently limited to EUA status for PEMGARDA, which could be revoked
- High cash burn in prior periods; future financing may be needed depending on VYD2311 commercialization plans
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3250025 |
Track record
19 reports on IVVD
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +35.85% at T+20 after the Jul 6, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 16, 2026today Press Release Neutral 6/10 Entry $0.5603 Now $0.5380 −3.98% settles Nov 23
- Nov 3, 202613d ago Press Release Neutral 2/10 Entry $0.5815 to $0.5744 Now $0.5380 −7.48% ▼ −1.22% −0.63% vs SPY
- Sep 29, 20266w ago 8-K Bullish 7/10 Entry $0.8501 to $0.8064 Now $0.5380 −36.71% ▼ −5.14% −7.09% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 3/10 Entry $0.9640 to $0.8501 Now $0.5380 −44.19% ▼ −11.82% −10.63% vs SPY
- Sep 1, 202610w ago 8-K Neutral 6/10 Entry $0.8800 to $0.7973 Now $0.5380 −38.86% ▼ −9.40% −9.48% vs SPY
- Aug 17, 202613w ago 144 Neutral 2/10 Entry $0.8680 to $0.9387 Now $0.5380 −38.02% ▲ +8.15% +8.35% vs SPY
- Jul 6, 202619w ago 8-K Bearish 6/10 Entry $0.8340 to $0.7834 Now $0.5380 +35.49% ▲ +6.07% +6.56% vs SPY
- Jun 16, 202621w ago Press Release Neutral 5/10 Entry $0.8918 to $0.9346 Now $0.5380 −39.67% ▲ +4.80% +7.03% vs SPY
- Jun 11, 202622w ago Institutional Cluster Mixed 4/10 Entry $0.8125 to $0.9312 Now $0.5380 −33.78% ▲ +14.61% +14.18% vs SPY
- Jun 9, 202622w ago Press Release Neutral 4/10 Entry $0.9900 to $0.8686 Now $0.5380 −45.66% ▼ −12.26% −14.67% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers